Get started

Dividendstocks

MO Long! [Target: $50] Looks like the formation of an ascending triangle bottom reversal. In addition to the chart pattern, this stock currently has an 8.1% dividend yield. If this stock trades sideways you can still book an 8% annual return. Never mind the ability for this company to enter the marijuana market at scale. As I've mentioned in other posts, I expect to see some capital flow from growth stocks to value stocks. MO is a great target for those looking for cash flow and large dividend payments. This is a great way to diversify your portfolio. **Not financial advice, do your own research**
NYSE:MOLong
by jfs2152
Uniliever (UL) - Long-term buy and hold OppThe company that has brought you amazing products such as Dove soap, Lipton Tea, Ben & Jerry's, Vaseline, and many many more products is presenting a good opportunity to invest in them. My technicals are showing that they are undervalued with potential bullish divergence. As I stated, i would be looking for support to be created before i purchase more shares. 2021 is starting off with really good buy setups for the long run! Invest Wisely! #BmoreWealthy
NYSE:ULLong
by primetimesosa
1
Uniliever (UL) - Long-term buy and hold OppThe company that has brought you amazing products such as Dove soap, Lipton Tea, Ben & Jerry's, Vaseline, and many many more products is presenting a good opportunity to invest in them. My technicals are showing that they are undervalued with potential bullish divergence. As I stated, i would be looking for support to be created before i purchase more shares. 2021 is starting off with really good buy setups for the long run! Invest Wisely! #BmoreWealthy
NYSE:ULLong
by primetimesosa
Long Bristol Myers for 2021 and beyond- Technical w/FundamentalBristol Myers is in a great position both fundamentally and technically. Time horizon is 1-2 years. Technical: Ascending Triangle with Price above the 30-day and 210-day simple moving averages. This could squeeze into the previous highs set in 2018 and 2016 (~$75). We want to see the price continue to stay above these averages as well as the trend line connecting the recent higher lows. Fundamental: -Recent Celgene acquisition adds $18B in revenue and diversifies BMY's product portfolio. Before the acquisition, BMY's Top 3 Drugs made up almost 75% of its total revenue. After the acquisition this same ratio is only 43%, decreasing BMY's reliance on its top 3 drugs. -Last three years the average P/E based on operating earnings for BMY has been 14.21, and at their current price they are trading at a 9.79, suggesting they may be currently undervalued. -Dividend of $1.92 or 3.14% yield -21.41% Adjusted Operating Earnings growth rate -A+ S&P credit rating Price Target = $100-110
NYSE:BMYLong
by kylespangladesh
Indication of price movement Q1 2021, AholdWe can see a symmetrical triangle forming on the charts of AHOLD. This can lead to a breakout or breakdown. In my personal opinion i think we will see a breakout, taking into account COVID-19 and AHOLD's strong position in online retail with 'bol.com'(Notoriously used by dropshippers), revenue growth is very likely. Also the strengthening of their position on the US market within the niche of fresh groceries deliveries is a smart move IMO. Giving the hype and attention to a increasingly healthy and sustainable lifestyle, the acquisition of FreshDirect based in the state of New York gives AHOLD a nice incline within that market segment. Fundamentals are strong and BETA is low. As of writing date dividend levels stand around 4%. Overall: Nice defensive stock with increasingly growth potential.
EURONEXT:ADLong
by Borntowinn
Storebrands strong dividends to support 56 NOK price tag?Storebrands operates in banking, asset management and insurance. The insurance segment has filled up its coffers according to the solvency II regulation, meaning there should be plentiful of cash accessible in the future for dividends which should interest investors looking for good cash flow and dividends. The trade is not a super exciting trade but feels like a rather certain one at current prices which is low by historic standards. The main risk with the trade is negative interest rates which could affect the insurance operations negatively. The main opportunity is a change in investor sentiment towards companies with strong cash flow and dividends. I set my first price target at 56 Norwegian crowns (NOK) which is around recent highs. My stop loss is set beneath the trend line (see the chart) and beneath recent support at 48 NOK. Long term I believe that the Storebrand will trade higher, perhaps reach 60 NOK in 2020. However, the path there is not very likely without retracement. I will use retracements as buying opportunities provided that the overall trade fundamentals remain intact throughout 2020.
OSL:STBLong
by UnknownUnicorn3806802
Good Div, High expectations & free cash flow : AROC5-star analyst T J Schultz, of RBC Capital, believes AROC has a firm foundation to move forward. He writes of the stock, “We expect lower associated gas production to have an impact on AROC utilization into 2021, but we think manageable debt leverage and ample dividend coverage provide some flexibility… we think the risk-reward is decent at current levels given AROC’s liquidity, lack of near-term debt maturities, and ability to pull additional levers to manage liquidity further if needed.” Schultz’s Buy rating on the stock is supported by an $11 price target, which suggests an impressive 68% upside potential for the year. Overall, the Strong Buy analyst consensus rating on AROC is unanimous, based on 3 recent Buy reviews. Shares are priced at $6.55, and the $9.17 average price target implies a one-year upside of 40%.
NYSE:AROC
by BigManAlasad
Trading at Pre-Covid Levels w/ Volume profile support +2.9% DiviEV/Sales Consensus.. sitting at 5.1x WHY QCOM?? Qualcomm pushes 5G tech into chips for cheaper phones June 16 (Reuters) - Qualcomm Inc on Tuesday said it is putting 5G technology into chips for smartphones that will sell for as little as $300 and that will come to market in the second half of this year. San Diego-based Qualcomm is the biggest supplier of processors for smartphones and the modem chips that connect the phones to wireless data networks. The company's chips featuring fifth-generation (5G) cellular telecommunications technology are currently in many premium-priced smartphones such as Samsung Electronics Co Ltd's Galaxy devices. But Qualcomm has also been working to get the technology into cheaper devices. The new chip, called the Snapdragon 690, will go into devices that it expects to retail at $300 to $500, Qualcomm said. Phone makers such as HMD Global, the owner of the Nokia phone brand, LG Electronics Inc and Lenovo Group Ltd's Motorola plan to use the chips, Qualcomm said. The push into lower price points means higher volumes for Qualcomm. According to data from Counterpoint Research, smartphones with wholesales prices of $100 to $400, which are somewhat lower than the prices consumers pay, made up about 50% of the overall smartphone market in the first quarter of 2020.
NASDAQ:QCOMLong
by SwingingForward
Merck has upside to $82Analyst forecasts for Merck earnings came down sharply early this year, but lately they've stabilized and even ticked upward a little. Merck is still priced for an optimistic market, with forward P/E around 15 and PEG around 2-3. This is reasonable for a large cap company with 3% dividend and a great reputation, but it's not bargain pricing, exactly. A second round of lockdowns or a second wave of Covid-19 could hurt the stock again. But as long there's no major deterioration of the macroeconomic outlook, the fair value range for Merck is about $75-82 per share. Analysts have been slow to make any forecasts for 2022 due to macroeconomic uncertainty, but I predict that the top end of the fair value range will shift upward to $87 per share once the 2022 forecasts finally come in. Merck is oversold today on the hourly RSI and curling upward. MACD is below the signal line, but also curling upward. A few minutes ago Merck announced an FDA approval to expand the label for GARDASIL, its HPV drug. I suspect this may function as a catalyst to send Merck back upward toward $82 per share. I bought some shares after-hours, and if I can get in cheap enough, I will consider some call options tomorrow with maybe a one-month expiration.
NYSE:MRKLong
by ChristopherCarrollSmith
3
BMY at volume support with strong fundamentalsBristol Myers-Squibb got another FDA approval yesterday to expand the label for its immunotherapy drug Opdivo. The approval isn't a huge deal, but it would have been an upward catalyst on a normal stock market day. BMY remains a highly rated stock by analysts, at just 10 forward P/E, 1.17 PEG, and 3% dividend yield. One drawback of BMY is that it has a -1.5% ESP prediction from Zacks, which means its slightly more likely than average to miss its next earnings forecast. I also think we're likely to see some negative sentiment on pharmaceuticals as the Democrats show strength at the polls. My trading plan for BMY is to buy some here, and then triple my position at the $51 volume support node.
NYSE:BMYLong
by ChristopherCarrollSmith
GEO Group IncFirst off, I view REITs in general as completely undervalued in our markets and due a solid run. Now with GEO I see them weathering the "storm" of covid-19 due to them being in a safe niche. They are heavily involved in the "for profit prisons" which I don't see going away any time soon (opposite of commercial office buildings). GEO also has a high dividend yield of over 17% which protects any slight drawdown. Technically speaking, the monthly candle is consolidating over a historic support/resistance zone. The zone originally acting as reistance, which led to a drawdown of -88% and a 7 year bear market. Acting as heavy support, GEO has seen surges of 175% and 221% from this zone. Add in a sub 35 RSI with volume steady increasing and the bull case gets stronger by the day.
NYSE:GEOLong
by wolf_rojo